CSPC Pharmaceutical Group (01093.HK): Albumin-bound Paclitaxel for Injection (II) Approved for Marketing
NewTimeSpace News: On June 15, 2026, CSPC Pharmaceutical Group (01093.HK) announced that its independently developed Albumin-bound Paclitaxel for Injection (II) has obtained marketing approval from the National Medical Products Administration. It is the world's first instant-dissolving albumin-bound paclitaxel preparation.
According to the announcement, key Phase III clinical trials demonstrated that this product delivers a superior objective response rate compared with similar drugs. It reduces the risk of death by 33%. The incidence of rash is cut by 62%, and the reconstitution time is shortened by 82%.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSPC Pharmaceutical Group (01093.HK): Receives US$30 Million Upfront Payment Under siRNA Collaboration Agreement with AstraZeneca
- CSPC Pharmaceutical Group (01093.HK): Phase I Clinical Trial of SYS6063 for Relapsed and Refractory Systemic Lupus Erythematosus Initiated at First Study Site in China
- CSPC Pharmaceutical Group (01093.HK): Monkeypox mRNA Vaccine SYS6037 Granted US FDA Clinical Trial Approval
- CSPC Pharmaceutical Group (01093.HK): Phase II Clinical Trial of Albumin-bound Sirolimus for Injection Officially Launched
- CSPC Pharmaceutical Group (01093.HK): Albumin-Bound Docetaxel Combined with Anitumab Granted Breakthrough Therapy Designation
